Tag Archives: cervarix

HPV: Not Just For Crotches Anymore

According to a new study, HPV is moving on up…to mouths! That’s right, just when you thought Gardasil and Cervarix solved all your problems, now you have to worry about what else you’ve been opening wide. Since the ’70s. throat cancer cases have doubled, and the research shows HPV is to blame, with 39% of all occurrences caused by the human papilloma virus. Before you go cutting your man off from his favorite foreplay, listen to this: men are 35% more likely than women to develop oral cancer from HPV. Sheesh, making a new man go downtown may be riskier than you both think! Still, there’s more bad news — as of yet, there is no way to test male genitalia for HPV or anyone’s throat to see if they’re a carrier. So, it’s a roll of the dice and doctors fear you may even be able to contract the virus from kissing. There goes all the fun! Since this throat cancer link is a new revelation, the cervical cancer vaccines haven’t been tested or proven to prevent it. So, deep throat, you might want to use a condom for oral sex or just give that random stranger a handy and call it a night! [ABC News] Keep reading »

FDA Guards Gardasil’s Market Share

So far in the states, Gardasil has been the only FDA approved vaccine for the double-whammy strain of HPV that causes cervical cancer. However, in Europe Cervarix has been kicking HPV’s butt and protecting women across the continent. While the drug has been in the FDA review process for foreva-eva, it looks like new data submitted by the makers, GlaxoSmithKline, will stall approvals now until 2009. Sheesh! What’s a girl gotta do to get some options? [Wall Street Journal]

Keep reading »

FDA Smackdown: Cervarix vs. Gardasil

The FDA is rushing to rubber stamp Gardasil, a cervical cancer vaccine, for women ages 27-45. Initially, the miracle HPV-preventer has been well received by its intended market — women and girls ages 9-26. Due to Gardasil’s success, amounting in $1.5 billion in sales last year, its makers, Merck & Co, are looking to expand potential beneficiaries. Merck has found Gardasil to be 91% effective in women 24-45 and are pushing for FDA approval within six months. The FDA is already reviewing a similarly effective British vaccine, Cervarix, put out by GlaxoSmithKline PLC, which is currently used for women up to 55 years of age in the U.K. No matter who wins the vaccine approval race, this is good news for women. With 250,000 reported deaths from cervical cancer every year, somethin’ has gotta be done! [ Boston Globe] Keep reading »

  • Zergnet: Simply Irresistible

  • HowAboutWe

  • Popular